<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892254</url>
  </required_header>
  <id_info>
    <org_study_id>PCOS-INK</org_study_id>
    <nct_id>NCT01892254</nct_id>
  </id_info>
  <brief_title>Incretin Effect in PCOS Women</brief_title>
  <official_title>Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom f√∏r og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the incretin effect in women with polycystic ovary syndrome (PCOS)&#xD;
      before and after removal of their insulin resistance by metformin.&#xD;
&#xD;
      The investigators' hypothesis is that insulin resistant women with PCOS have a reduced&#xD;
      incretin effect and elevated glucagon responses as measured by a 75-g oral glucose tolerance&#xD;
      test and isoglycemic i.v. glucose infusion. The investigators hypothesise that both can be&#xD;
      improved when their insulin resistance is removed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 23, 2017</completion_date>
  <primary_completion_date type="Actual">November 23, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in incretin effect from baseline and until after removal of insulin resistance</measure>
    <time_frame>baseline and 12 weeks' treatment</time_frame>
    <description>The incretin effect will be assessed from the insulin secretion during af 75 g OGTT and IIGI at baseline and after 12 weeks' treatment with placebo and metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon response</measure>
    <time_frame>0, 12 and 30 weeks</time_frame>
    <description>Glucagon responses (plasma concentrations) will be assessed during the 75-g OGTTs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin-Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin, 2x 2 tablets a day, 500 mg tablets</description>
    <arm_group_label>Metformin-Placebo</arm_group_label>
    <arm_group_label>Placebo-metformin</arm_group_label>
    <other_name>657-24-9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (to metformin)</description>
    <arm_group_label>Metformin-Placebo</arm_group_label>
    <arm_group_label>Placebo-metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria PCOS-women:&#xD;
&#xD;
          -  Diagnosed with PCOS according to the Rotterdam criteria&#xD;
&#xD;
          -  more than 18 years old&#xD;
&#xD;
          -  BMI less than 30 kg/m2&#xD;
&#xD;
          -  Normal glucose tolerance and fasting plasma glucose (assessed by 75-g OGTT)&#xD;
&#xD;
          -  Negative GAD65 and islet cell autoantibodies&#xD;
&#xD;
          -  Insulin resistant according to HOMA-IR&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Inclusion Criteria healthy women:&#xD;
&#xD;
          -  more than 18 years old&#xD;
&#xD;
          -  BMI less than 30 kg/m2&#xD;
&#xD;
          -  Normal glucose tolerance and fasting plasma glucose (assessed by 75-g OGTT)&#xD;
&#xD;
          -  Negative GAD65 and islet cell autoantibodies&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  regular menstrual cycle (28-35 days)&#xD;
&#xD;
          -  Plasma androgen levels within reference levels&#xD;
&#xD;
        Exclusion Criteria PCOS and healthy women:&#xD;
&#xD;
          -  First or second degree relatives with diabetes&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  treatment with medication which influences the glucose metabolism (incl hormonal&#xD;
             contraception)&#xD;
&#xD;
          -  Congenital diseases which cause hyperandrogenism and irregular bleeding&#xD;
&#xD;
          -  Known adrenal hyperplasia&#xD;
&#xD;
          -  Known hyperprolaktinemia&#xD;
&#xD;
          -  Alcohol consumption of more than 20 grams a day&#xD;
&#xD;
          -  Hemoglobin less than 7.8 %&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Vedtofte, MSc., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital, Gentofte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital Gentofte</name>
      <address>
        <city>Hellerup</city>
        <state>Select A State</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 11, 2013</study_first_submitted>
  <study_first_submitted_qc>June 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Louise Vedtofte</investigator_full_name>
    <investigator_title>Humanbiolog, ph.d.</investigator_title>
  </responsible_party>
  <keyword>incretin effect</keyword>
  <keyword>PCOS</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>OGTT</keyword>
  <keyword>IIGI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

